Genetic and genomic insights across the steatotic liver disease spectrum
Clinical and Molecular Hepatology · 2026
DOI: 10.3350/cmh.2026.0477 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical and Molecular Hepatology, 2026. Verfasst von Jake P Mann und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology & Immunotherapy, School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham,…. Hauptthemen laut MEDLINE: Fatty Liver. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 168 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: NIH HHS, AstraZeneca, GlaxoSmithKline.
Abstract (Originalsprache)
Chronic liver disease is a rapidly growing cause of morbidity and mortality worldwide, and this increase is largely driven by steatotic liver disease (SLD) comprising metabolic dysfunction-associated steatotic liver disease (MASLD), alcohol-related liver disease (ALD), and MASLD and increased alcohol intake (MetALD). Hepatic steatosis and fibrosis are highly heritable and genetic variation has also been associated with the risk of hepatocellular carcinoma (HCC) and hepatic decompensation. This review summarizes the state of the art of genetics and genomics in SLD, with particular emphasis on potential clinical utility. Variants in/near genes including PNPLA3, TM6SF2, and HSD17B13 have been associated with cirrhosis and HCC in both MASLD and ALD, while others such as those in GCKR, TRIB1, and GPAM have been consistently associated with greater risk of hepatic steatosis in MASLD with much weaker effects if any on cirrhosis and HCC. While data on MetALD genetics are limited, we believe that the genetic risk factors for liver steatosis, cirrhosis, and HCC will be similar in MetALD compared to MASLD and ALD based on the largely shared genetic risk factors for MASLD and ALD. Finally, we discuss future directions in SLD genetics, notably genetically-defined disease subtypes, gene-environment interactions and their implications for therapy, and the utility of genetics in clinical risk stratification. Genetic studies have provided insight into important disease processes in SLD and may have an upcoming role in clinical care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunology & Immunotherapy, School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham, Birmingham, UK.
- Liver Unit, Birmingham Women's and Children's NHS Foundation Trust, Birmingham, UK.
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, Banner University Medical Center, Phoenix, AZ, USA.
- Division of Gastroenterology and Hepatology, Department of Medicine, University of Arizona College of Medicine - Phoenix, Phoenix, AZ, USA.
- Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, USA.
- Department of Gastroenterology, Hepatopancreatology and Digestive Oncology, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium.
Förderung
- NIH HHS
- AstraZeneca
- GlaxoSmithKline
- NIDDK NIH HHS
- Ipsen
- Birmingham Health Partners
- University of Michigan Department of Internal Medicine
- KOWA
Zitieren
APA
Mann, J. P., Wijarnpreecha, K., Prasitsumrit, V., Trépo, E., Speliotes, E. K., & Chen, V. L. (2026). Genetic and genomic insights across the steatotic liver disease spectrum. Clinical and Molecular Hepatology. https://doi.org/10.3350/cmh.2026.0477
Vancouver
Mann JP, Wijarnpreecha K, Prasitsumrit V, Trépo E, Speliotes EK, Chen VL. Genetic and genomic insights across the steatotic liver disease spectrum. Clinical and Molecular Hepatology. 2026. doi:10.3350/cmh.2026.0477
BibTeX
@article{Mann2026,
author = {Mann, Jake P and Wijarnpreecha, Karn and Prasitsumrit, Vitchapong and Trépo, Eric and Speliotes, Elizabeth K and Chen, Vincent L},
title = {Genetic and genomic insights across the steatotic liver disease spectrum},
journal = {Clinical and Molecular Hepatology},
year = {2026},
doi = {10.3350/cmh.2026.0477}
}
EUVIMED